Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13722507 | 0.98 | MAOA (0.46) | MAOAMAOBCYP19A1CA1CA2 | |
| SCHEMBL589307 | 0.81 | MAOB (0.50) | MAOAMAOBCYP19A1CA1CA2 | |
| SCHEMBL30279898 | 0.81 | MAOB (0.50) | MAOAMAOBCYP19A1CA1CA2 | |
| SCHEMBL17571925 | 0.80 | ALDH1A1 (0.49) | LMNAALDH1A1 | |
| SCHEMBL23779534 | 0.79 | MAOB (0.52) | MAOAMAOBCYP19A1CA1CA2 | |
| SCHEMBL29634429 | 0.79 | MAOB (0.52) | MAOAMAOBCYP19A1CA1CA2 | |
| SCHEMBL18673914 | 0.79 | GABRA1 (0.37) | LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL20682262 | 0.79 | PNMT (0.53) | LMNATSHRCYP3A4RECQL | |
| SCHEMBL20682264 | 0.79 | ALDH1A1 (0.45) | LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL25820331 | 0.79 | HDAC4 (0.41) | CA1CA2CA9ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-2699554-B1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER IP GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2699554-B1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER IP GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2909183-B1 | 4-(ORTHO)-FLUOROPHENYL-5-FLUOROPYRIMIDIN-2-YL AMINES CONTAINING A SULFONE GROUP | Bayer Pharma AG (DE) | 2016-08-24 | — | — | EP | disclosed |
| EP-2755956-B1 | 2,4-DISUBSTITUTED 5-FLUORO-PYRIMIDINES AS SELECTIVE CDK9 INHIBTORS | BAYER IP GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2755956-B1 | 2,4-DISUBSTITUTED 5-FLUORO-PYRIMIDINES AS SELECTIVE CDK9 INHIBTORS | BAYER IP GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016035008-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
| US-20150259300-A1 | 4-(ORTHO)-FLUOROPHENYL-5-FLUOROPYRIMIDIN-2-YL AMINES CONTAINING A SULFONE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2909183-A1 | 4-(ORTHO)-FLUOROPHENYL-5-FLUOROPYRIMIDIN-2-YL AMINES CONTAINING A SULFONE GROUP | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-26 | — | — | EP | disclosed |
| WO-2013037896-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012143399-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259300-A1 | 4-(ORTHO)-FLUOROPHENYL-5-FLUOROPYRIMIDIN-2-YL AMINES CONTAINING A SULFONE GROUP | PAH, ABL1, OAT | MAOA 150/4885MAOB 37/4885CYP19A1 579/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MAOA 4268/4885MAOB 4512/4885CYP19A1 1394/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | MAOA 4628/4885MAOB 4029/4885CYP19A1 3664/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | MAOA 4268/4885MAOB 4512/4885CYP19A1 1394/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | MAOA 4635/4885MAOB 3908/4885CYP19A1 4074/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MAOA 4268/4885MAOB 4512/4885CYP19A1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.